Document Type : Original Article

Authors

1 Radiation Oncology Research Center (RORC), Cancer Research Institute, Tehran University of Medical Sciences, Tehran, Iran

2 Department of Radiation Oncology, Cancer Institute, Imam Khomeini Hospital Complex, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

3 School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Abstract

Background: Hypopharyngeal carcinoma (HPC) is a rare head and neck cancer which poses many therapeutic challenges. There is limited evidence regarding the outcomes of HPC treatment in Iran.
Method: In this retrospective cohort study, we evaluated patients treated with chemoradiation or radiation alone, between 2007 and 2016 in the radiation oncology ward of the cancer institute affiliated to Tehran University of Medical Sciences. The design of the study was reviewed and approved by the local institutional review board (code: 86100142). All patients underwent definitive radiotherapy with or without concurrent or sequential chemotherapy. We assessed the two-year overall survival (OS) as the primary outcome. The progression-free survival (PFS) was our secondary outcome.
Results: We studied 40 patients whose median age was 58 years. 37 patients were stage 3 or 4, while the most common stage was T3N1-2, observed in 35% of the cases. The most common site of involvement was pyriform sinus (47.5%). The twoyear OS rate was 29%. The two-year PFS was 22%. In the univariate analysis, N0-1 vs. N 2-3 and stage 2 vs. stage 3-4 were significant predictors of OS. In addition, distant metastasis had almost a significant association with lower OS.
Conclusion: The outcome of locally advanced HPC was not promising using 3DCRT alone. It is necessary to implement dramatic changes in the management of these patients to achieve better outcomes.

Keywords

How to cite this article:

Kazemian A, Ghalehtaki R, Razmkhah M, Taheriyoun M, Mohammadi N, Narimani Kali M, et al. Definitive radiotherapy with or without concomitant or induction chemotherapy in patients with hypopharyngeal squamous cell carcinoma: a single center study in Iran. Middle East J Cancer. 2022;13(2):308-15. doi: 10.30476/mejc.2020.87158.1404.

1. Popescu CR, Bertesteanu SV, Mirea D, Grigore R,
lonescu D, Popescu B. The epidemiology of
hypopharynx and cervical esophagus cancer. J Med
Life. 2010;3(4):396-401.
2. Jang JY, Kim EH, Cho J, Jung JH, Oh D, Ahn YC, et
al. Comparison of oncological and functional outcomes
between initial surgical versus non-surgical treatments
for hypopharyngeal cancer. Ann Surg Oncol.
2016;23(6):2054-61. doi:10.1245/s10434-016-5088-
4.
3. Mozaffari HR, Izadi B, Sadeghi M, Rezaei F, Sharifi
R, Jalilian F. Prevalence of oral and pharyngeal cancers
in Kermanshah province, Iran: A ten-year period. Int
J Cancer Res. 2016;12(3–4):169-75.
4. Shangina O, Brennan P, Szeszenia-Dabrowska N,
Mates D, Fabiánová E, Fletcher T, et al. Occupational
exposure and laryngeal and hypopharyngeal cancer
risk in central and eastern Europe. Am J Epidemiol.
2006;164(4):367-75. doi:10.1093/aje/kwj208.
5. Klussmann JP, Weissenborn SJ, Wieland U, Dries V,
Kolligs J, Jungehuelsing M, et al. Prevalence,
distribution, and viral load of human papillomavirus
16 DNA in tonsillar carcinomas. Cancer. 2001;92(11):
2875–84.
6. Garden AS. Organ preservation for carcinoma of the
larynx and hypopharynx. Hematol/Oncol Clin North
Am. 2001;15(2):243-60.
7. Carvalho AL, Nishimoto IN, Califano JA, Kowalski
LP. Trends in incidence and prognosis for head and
neck cancer in the United States: A site-specific analysis
of the SEER database. Int J Cancer. 2005;114(5):806-
16.
8. Mirzaei M, Hosseini SA, Ghoncheh M, Soheilipour
F, Soltani S, Soheilipour F, et al. Epidemiology and
trend of head and neck cancers in Iran. Glob J Health
Sci. 2015;8(1):189-93. doi: 10.5539/gjhs.v8n1p189.
9. Hoffman HT, Karnell LH, Shah JP, Ariyan S, Brown
GS, Fee WE, et al. Hypopharyngeal cancer patient
care evaluation. Laryngoscope. 1997;107(8):1005-17.
doi: 10.1097/00005537-199708000-00001.
10. Zelefsky MJ, Kraus DH, Pfister DG, Raben A, Shah
JP, Strong EW, et al. Combined chemotherapy and
radiotherapy versus surgery and postoperative
radiotherapy for advanced hypopharyngeal cancer.
Head Neck. 1996;18(5):405-11. doi: 10.1002/(SICI)
1 0 9 7 - 0 3 4 7 ( 1 9 9 6 0 9 / 1 0 ) 1 8 : 5 < 4 0 5 : : A I D -
HED3>3.0.CO;2-9.
11. Bova R, Goh R, Poulson M, Coman WB. Total pharyngolaryngectomy
for squamous cell carcinoma of the
hypopharynx: A review. Laryngoscope.
2005;115(5):864-9. doi:10.1097/01.MLG.0000158348.
38763.5D.
12. Makeieff M, Mercente G, Jouzdani E, Garrel R,
Crampette L, Guerrier B. Supraglottic hemipharyngolaryngectomy
for the treatment of T1 and T2
carcinomas of laryngeal margin and piriform sinus.
Head Neck. 2004;26(8):701-5.
13. Gupta T, Chopra S, Agarwal JP, Laskar SG, D’Cruz
AK, Shrivastava SK, et al. Squamous cell carcinoma
of the hypopharynx: Single-institution outcome analysis
of a large cohort of patients treated with primary nonsurgical
approaches. Acta Oncol (Madr). 2009;48(4):
541-8.
14. Krstevska V, Stojkovski I, Lukarski D. Concurrent
radiochemotherapy in advanced hypopharyngeal
cancer. Radiat Oncol. 2010;5(1):39.
15. Studer G, Lütolf UM, Davis JB, Glanzmann C. IMRT
in hypopharyngeal tumors. Strahlenther Onkol. 2006;
182(6):331-5. doi: 10.1007/s00066-006-1556-2.
16. Mok G, Gauthier I, Jiang H, Huang SH, Chan K,
Witterick IJ, et al. Outcomes of intensity-modulated
radiotherapy versus conventional radiotherapy for
hypopharyngeal cancer. Head Neck. 2015;37(5):655-
61. doi: 10.1002/hed.23649.
17. Bhayani MK, Hutcheson KA, Barringer DA, Roberts
DB, Lewin JS, Lai SY. Gastrostomy tube placement in patients with hypopharyngeal cancer treated with
radiotherapy or chemoradiotherapy: factors affecting
placement and dependence. Head Neck. 2013;35(11):
1641-6. doi: 10.1002/hed.23199.
18. Bozec A, Benezery K, Chamorey E, Ettaiche M,
Vandersteen C, Dassonville O, et al. Nutritional status
and feeding-tube placement in patients with locally
advanced hypopharyngeal cancer included in an
induction chemotherapy-based larynx preservation
program. Eur Arch Oto-Rhino-Laryngology. 2016;
273(9):2681-7.